| Name | Title | Contact Details |
|---|---|---|
Gianela G. |
Human Resources | Profile |
Alexander Azoy |
Chief Accounting Officer (CAO) | Profile |
Jeffrey Lammers |
Director, Clinical Supply Chain Operations | Profile |
Ester Fernandez-Salas |
Senior Director R&D Biology | Profile |
manshiu leung |
Executive Director, Small Molecule Drug Product Development & GMP Ma | Profile |
UNITY Biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. UNITY`s initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases.
Mirna Therapeutics, Inc. (Mirna) is a biotechnology research and development company focused on miRNA-directed oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and a broad IP portfolio, Mirna Therapeutics is well-positioned to capitalize on the emerging field of miRNA-based therapeutics.
At Outpost, we are committed to developing novel therapeutics for the treatment of gastrointestinal and urologic disorders. The company`s lead clinical-stage product candidate is in development for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). Located in Indianapolis and London, Outpost is a private company launched in 2016 with a $61 million Series A venture capital financing from Frazier Healthcare Partners, Adams Street Partners, Novo Holdings A/S, Vivo Capital, and Takeda Ventures.
Precision NanoSystems Inc. (PNI) creates innovative solutions that empower researchers to harness powerful nanotechnology to transform our understanding and treatment of diseases.
NexBio, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.